Business Context and Reporting Period
This Form 10-Q covers the quarterly and six-month periods ended June 30, 1996, for OXIS International, Inc. (Note: The input metadata lists "GT Biopharma, Inc.", but the filing text explicitly identifies the registrant as OXIS International, Inc.). The Company is a biotechnology firm focused on developing therapeutic products, including bovine superoxide dismutase (bSOD) and glutathione peroxidase mimics. The financial statements are prepared on a going concern basis, contingent upon the Company's ability to secure additional financing.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1996 | Six Months Ended June 30, 1996 |
|---|---|---|
| Total Revenues | $1,228,000 | $2,595,000 |
| Net Loss | $(1,519,000) | $(3,065,000) |
| Net Loss Per Share | $(0.12) | $(0.25) |
| Cash and Cash Equivalents | $1,129,000 (Balance Sheet) | $1,129,000 (Balance Sheet) |
| Working Capital | $258,000 (Positive) | $258,000 (Positive) |
| Notes Payable | $296,000 | $296,000 |
| Convertible Debentures | $0 | $0 |
Liquidity: Cash increased from $727,000 at December 31, 1995, to $1,129,000 at June 30, 1996. Net cash used in operating activities was $2,122,000 for the six-month period, offset by $2,489,000 in net cash provided by financing activities.
Material Changes vs. Prior Period
- Revenue: For the six months ended June 30, 1996, total revenues decreased by $617,000 (19%) compared to the same period in 1995. Product sales dropped from $3,140,000 to $2,537,000, primarily due to the cessation of bulk bSOD sales to Sanofi Winthrop Inc. following a failed Phase III trial.
- Expenses: Research and development (R&D) expenses increased by $342,000 (17%) to $2,361,000 for the six-month period, driven by preclinical development of lead therapeutics and costs associated with the acquired Therox Pharmaceuticals operations.
- Net Loss: The net loss widened by $846,000 to $3,065,000 for the six months ended June 30, 1996, compared to $2,219,000 in the prior year period.
- Debt Reduction: The Company significantly reduced interest-bearing obligations. $1,255,000 in convertible debentures were converted to common stock, and $766,000 in notes were cancelled in exchange for Series C Preferred Stock.
Guidance, Outlook, and Risks
- Capital Needs: Management explicitly states the Company must raise additional capital during the third quarter of 1996 to continue operations. Failure to do so may force the Company to curtail operations, reduce personnel, or seek bankruptcy protection.
- Revenue Outlook: Future revenues are uncertain. Sales of bSOD to Sanofi Winthrop are not expected to continue. Future bulk bSOD sales to other distributors are described as "uncertain and difficult to predict."
- Going Concern: The filing includes a "going concern" warning. The Company has incurred losses for three consecutive years and relies on private placements of equity securities to fund operations.
- Recent Financing: In the first six months of 1996, the Company raised approximately $3.2 million through the sale of Series C and Series D Preferred Stock.
Investor Verification Checklist
- Verify the Company's ability to secure the necessary additional capital in Q3 1996 to avoid operational curtailment.
- Confirm the status of business alliance negotiations for new products, as future revenue depends on these partnerships.
- Monitor the conversion terms and potential dilution from the recently issued Series C and Series D Preferred Stock.
- Assess the impact of the failed Sanofi Winthrop trial on long-term revenue projections for bSOD.
- Review the progress of the lead therapeutics program (glutathione peroxidase mimics) given the increased R&D spend.